Koido Shigeo, Homma Sadamu, Okamoto Masato, Namiki Yoshihisa, Takakura Kazuki, Uchiyama Kan, Kajihara Mikio, Arihiro Seiji, Imazu Hiroo, Arakawa Hiroshi, Kan Shin, Komita Hideo, Ito Masaki, Ohkusa Toshifumi, Gong Jianlin, Tajiri Hisao
Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan ; Institute of Clinical Medicine and Research; The Jikei University School of Medicine; Tokyo, Japan ; Department of Oncology, Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan.
Oncoimmunology. 2013 May 1;2(5):e24437. doi: 10.4161/onci.24437.
Various strategies have been developed to deliver tumor-associated antigens (TAAs) to dendritic cells (DCs). Among these, the fusion of DCs and whole cancer cells can process a broad array of TAAs, including hitherto unidentified molecules, and present them in complex with MHC Class I and II molecules and in the context of co-stimulatory signals. DC-cancer cell fusions have been shown to stimulate potent antitumor immune responses in animal models. In early clinical trials, however, the antitumor effects of DC-cancer cell fusions are not as vigorous as in preclinical settings. This mini-review summarizes recent advances in anticancer vaccines based on DC-cancer cell fusions.
人们已经开发出多种策略将肿瘤相关抗原（TAA）递送至树突状细胞（DC）。其中，DC与完整癌细胞的融合可处理多种TAA，包括迄今尚未鉴定的分子，并将它们与MHC I类和II类分子形成复合物并在共刺激信号的背景下呈递。DC-癌细胞融合已被证明可在动物模型中刺激强大的抗肿瘤免疫反应。然而，在早期临床试验中，DC-癌细胞融合的抗肿瘤作用不如临床前研究中那么显著。本综述总结了基于DC-癌细胞融合的抗癌疫苗的最新进展。
